Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of G-202 in Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
2011-002149-36Phase 2Terminated
- Sponsor
- Inspyr Therapeutics
- Start
- Jul 2012
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mipsagargin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Inspyr Therapeutics. Started Jul 2012; status: terminated.
02
Drugs
mipsagargin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-002149-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002149-36.